Posterior Femoral Region / Hamstring Tendinopathy / PRP+HA / VAS+VISA-H

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP and Hyaluronic Acid for Hamstring Tendinopathy.  

The Platelet Rich Plasma “PRP” Market is valued at 828.8 Billion in 2023, and is estimated to grow to over 3 Trillion by 2032. The HA Market is currently estimated at 11.14 Billion (2025) and predicted to grow to about 19.94 Billion by 2034. Hamstring Tendinopathy is a common indication among athletes and active adults, though it affects everyone. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Hamstring Tendinopathy. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Hamstring Tendinopathy cases, outcomes and other case data.